Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 23, 2022BloodOpen Access

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJohn F. SeymourTKThomas J. KippsBEBarbara Eichhorst

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Seymour et al. (2022) studied this question.

synapsesocial.com/papers/6a8502bc80907ad94f0cc2e4https://doi.org/10.1182/blood.2021015014
View Full Paper
Ask AI
Bookmark
Share